NDAORALCAPSULE
Approved
Feb 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ALLI (orlistat) by GSK is lipase inhibitors [moa]. Approved for obesity, overweight. First approved in 2007.
Drug data last refreshed 23h ago
Mechanism of Action
Lipase Inhibitors
Pharmacologic Class:
Intestinal Lipase Inhibitor
Indications (2)
Clinical Trials (20)
ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
Started Jan 2027
125 enrolled
Mitral RegurgitationMitral Valve DiseaseMitral Stenosis
Single Arm, Monocentric, Pilot Feasibility Study on an Interactive Virtual Reality Program in 20 Complex In-clinic Palliative Care Patients
Started Sep 2026
20 enrolled
Palliative CareRefractory PainAnxiety+3 more
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke
Started May 2026
220 enrolled
Acute Ischemic Stroke
Palliative Care Intervention to Improve Health Related Quality of Life for Patients on Long-Term LVAD Support
Started Mar 2026
90 enrolled
Advanced Heart FailureMechanical Circulatory SupportLeft Ventricular Assist Device+1 more
Evaluating the Impact of "CHUT OTONOM®" Footwear on the Spatio-temporal Parameters of Walking and the Risk of Falls in Elderly People at High Risk of Falling.
Started Jan 2026
Worked on ALLI at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.